Cell Source

Cell Therapy Treatments Based on Immune Tolerance

Health Tech & Life Sciences
Active
Public Bnei Brak, Israel Founded 2011
Website ↗
Last updated 2026-06-18
Total raised
$21.5M
Stage
Public
Founded
2011
Headcount
20
HQ
Bnei Brak, Israel
Sector
Health Tech & Life Sciences

About

Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company's patented Veto Cell technology enables safe and selective tuning of immune responses. Veto Cells are white blood cells taken from either the patient or a healthy third-party donor. They are then processed using a proprietary mix of off-the-shelf, FDA-approved cytokines that change their characteristics and activate their inherent attacker-blocking capability. Once reintroduced into the body intravenously, they can perform a number of important functions. Potential applications range from facilitating bone marrow and organ transplantation to effectively treating blood cancers such as lymphoma and nonmalignant congenital diseases such as sickle cell anemia.

Q&A

What is Cell Source's primary focus?
Cell Source is a biotechnology company that focuses on developing cell therapy treatments based on the management of immune tolerance.
What is Cell Source's core technology?
Cell Source's core technology is its patented Veto Cell technology, which enables the safe and selective tuning of immune responses.
What are the potential applications of Cell Source's Veto Cell technology?
Potential applications of Cell Source's Veto Cell technology include facilitating bone marrow and organ transplantation, and treating blood cancers like lymphoma and nonmalignant congenital diseases such as sickle cell anemia.
When was Cell Source founded?
Cell Source was founded in September 2011.
What is Cell Source's current employee count?
Cell Source has 11-50 employees.
What is the total amount of funding Cell Source has raised?
Cell Source has raised a total of $21,540,000 USD.
What is Cell Source's current market capitalization?
Cell Source's market capitalization is $22,519,122 USD.
When did Cell Source become a public company?
Cell Source became public on OTC in May 2014.
Where is Cell Source headquartered?
Cell Source is headquartered in Bnei Brak, Israel.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentBiomaterials & Tissue Engineering
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B

Highlights

1 Patents

Tags

immunologybiological-therapyregenerative-medicinecell-therapycancerpharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitecell-source.com

Identifiers & details

Founded2011-9
Employees (exact)20
OfficesNew York
Market cap$22.5M
Status reasonPublic on OTC on May, 2014;

Radar intelligence

Patents

EPO27

Web history (Wayback)

Domaincell-source.com

Certificate / subdomain footprint

Subdomains1